Kelly Ke

Kelly Ke is the founder of bizi LLC, working at the intersection of health policy and strategic decision-making to support life sciences companies navigating China market access. Her co-authored Caixin article on the C-List roadmap sparked substantive discussion across China’s policy and industry circles. A former award-winning Deloitte U.S. life sciences advisor, she is the architect of the NRDL+ Executive Debrief, a strategic intelligence platform focused on China’s evolving multi-layer coverage system.